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ABSTRACT The functions of neurotransmitters in fetal
development are poorly understood. Genetic observations
have suggested a role for the inhibitory amino acid neuro-
transmitter g-aminobutyric acid (GABA) in the normal de-
velopment of the mouse palate. Mice homozygous for muta-
tions in the b-3 GABAA receptor subunit develop a cleft
secondary palate. GABA, the ligand for this receptor, is
synthesized by the enzyme glutamic acid decarboxylase. We
have disrupted one of the two mouse Gad genes by gene
targeting and also find defects in the formation of the palate.
The striking similarity in phenotype between the receptor and
ligand mutations clearly demonstrates a role for GABA sig-
naling in normal palate development.
The neurotransmitter g-aminobutyric acid (GABA) has many
critical functions as an intercellular signaling molecule in the
nervous system and is thought to be involved in cell signaling
in a number of nonneuronal cell types (1). In addition, a role
for GABA has been suggested in the development and dif-
ferentiation of the nervous system (2–4). In the central ner-
vous system, GABA is the primary inhibitory neurotransmitter
and has a critical role in the regulation of neural activity.
Outside of the nervous system a number of cell types synthesize
GABA. For example, GABA is made by the pancreatic b cells
and appears to act as a signaling molecule between cells within
the pancreatic islets (5, 6). This b cell-specific expression of
GABA and glutamic acid decarboxylase (GAD) underlies the
destruction of these cell types in autoimmune insulin-
dependent diabetes by GAD autoantibodies (7). Several ob-
servations have also suggested that GABA plays a role in
normal embryonic and fetal development. Cell culture studies
have demonstrated that GABA can promote the survival,
differentiation, and migration of embryonic neurons (2, 4, 8).
In addition, both genetic and teratological studies have shown
that GABA signaling may be involved in normal craniofacial
development (9–14).
To further study the roles of GABA in normal develop-
ment and physiology, we have taken a genetic approach. This
approach is necessary due to the current lack of specific
inhibitors of GAD enzyme activity (15). In mice, two distinct
GAD enzymes are encoded by two separate genes, Gad65
and Gad67 (16). We have used gene targeting to inactivate
Gad67 and find that the homozygous mutants exhibit a
developmental phenotype characterized by neonatal death
and a highly penetrant cleft secondary palate. Previous
observations have suggested a role for GABA in palate
development. Some of these earlier studies showed that
drugs potentiating GABA action can induce cleft palate
during a critical period of mouse palate development (12–
14). However, these studies used high drug doses to produce
the cleft palate phenotype, suggesting that the effect might
be nonspecific. The analysis of mice with mutations in the
b-3 GABAA receptor demonstrated that these mutations are
associated with cleft secondary palate in mice (9–11). The
phenotype in these receptor mutants showed that this gene
is somehow involved in palate development but did not
demonstrate that GABA was the ligand involved in this
particular function. Our results strengthen and extend the
previous studies by clearly demonstrating that GABA has a
critical role in the normal development of the mouse palate.
MATERIALS AND METHODS
Construction of the Gad67 Mutant Mice and Histological
Analysis. A Gad67 genomic clone was isolated from an
embryonic stem (ES) cell genomic library. The targeting
vector was constructed by inserting the pMC1Neo poly(A)
gene (17) into a BamHI site in the first protein coding exon of
the Gad67 gene (18). The herpes simplex virus (HSV) 1 and
HSV2 thymidine kinase genes were added to this construct to
provide negative selection. R1 ES cells (19) were electropo-
rated with the Gad67 targeting vector and clones doubly
resistant to G418 and 1-(2-deoxy-2-f luoro-b-D-arabinfurano-
syl)-5-iodouracil (FIAU) were selected. Of 129 double-
resistant ES cell colonies, 9 contained a targeted disruption of
the Gad67 gene as determined by Southern blot analysis. Two
of these clones were injected into C57BLy6 host blastocyst
embryos to generate chimeras. Several of these chimeras
passed the Gad67 mutation to their offspring, as determined
by Southern blot or PCR analysis. These mice were inter-
crossed to produce Gad67 homozygotes and control litter-
mates. The Gad67 mutation is maintained on a hybrid 129yB6
genetic background.
Whole-mount skeleton preparations were made as described
(20). Fetal and newborn mice were fixed in 4% formaldehydey
PBS and dissected to examine the palates. Gestation time was
determined with the assumption that noon of the day a plug
was found equals 0.5 day of development.
RNase Protection Analysis. A probe corresponding to nu-
cleotides 33–253 of the cDNA sequence of Katarova et al. (18)
was hybridized to 5 mg of adult brain total RNA or 25 mg of
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total RNA from embryonic day (E) 18.5 day fetal heads. This
probe corresponds to the region of the Gad67 mRNA that is
disrupted by the Neo cassette in the mutant allele. The Gad65
probe was as described (21). The GAPDH probe was pur-
chased from Ambion (Austin, TX).
RESULTS AND DISCUSSION
Mice with a loss-of-function mutation in the Gad67 gene were
generated by gene targeting in embryonic stem cells (Fig. 1).
The homologous recombination event inserted a neo cassette
into the first protein-coding exon of the Gad67 gene in ES cells
(Fig. 1 B–D). These ES cells were injected into host embryos
to generate chimeric mice and several chimeras passed the
mutation to their progeny, generating a colony of mice het-
erozygous for the Gad67 mutation.
The Gad67 heterozygotes were intercrossed and Gad gene
expression was examined in the progeny. In mice, two distinct
GADs are encoded by two separate genes, Gad67 and Gad65
(16). We determined the effect of the Gad67 mutation on
expression of Gad67 and Gad65 mRNA in mouse fetuses. In
an RNase protection assay, a probe spanning the site of the neo
insertion did not protect any intact Gad67 transcripts in RNA
from Gad67 (2y2) E18.5 mouse heads (Fig. 2B). An RNase
protection analysis of the other Gad gene, Gad65, was per-
formed to detect any compensatory changes in its expression
in the mutants. Gad65 expression was not altered in the Gad67
homozygotes, showing that no compensatory mechanism ex-
ists to alter its RNA expression level in the Gad67 mutants
(Fig. 2C). This analysis indicates that the disruption of the
Gad67 locus eliminates the expression of intact Gad67 RNA
without altering the level of Gad65 mRNA expression.
In addition to Gad gene expression, the viability and out-
ward phenotype of the Gad67 mutants was examined. The
Gad67 homozygous mutants die shortly after birth. Genotype
analysis of the progeny of Gad67 heterozygote intercrosses
shows that no homozygotes were recovered at weaning (Table
1). However, nearly expected numbers of homozygotes were
recovered shortly after birth and normal numbers were found
in litters removed by caesarean section late in gestation (Table
1). Gad67 (2y2) E18.5 day fetuses, delivered by caesarean
section, were always distinguishable from their littermates,
retaining after delivery a blue skin color suggesting hypoxia.
Newborn homozygotes that survived birth failed to nurse,
leading to fatal dehydration and frequently aspirated air into
their intestinal tract. Bloating of the intestinal tract is observed
in other mutant mouse strains with cleft palates (22). A
preliminary histological examination of two Gad67 homozy-
gotes revealed no gross defects in brain morphology. A more
detailed examination of nervous system anatomy and function
in these mice is underway.
The cleft palate phenotype found in the b-3 GABAA
receptor subunit mutants (10, 11) prompted a careful exami-
FIG. 1. Gene targeting at the Gad67 locus. (A) The Gad67 targeting vector. The pMC1NeoPoly(A) cassette (NEO) was inserted into the first
coding exon of the Gad67 gene (solid boxes). HSV1 and HSV2 thymidine kinase genes (TK1 and TK2) were added flanking the homology. The
shaded region is plasmid vector sequence. (B) Southern blot analysis of gene targeting at Gad67. Genomic DNA was isolated from the parental
ES cell line and from the ES cell lines 1g3 and 2d3 containing the disrupted Gad67 allele. DNA was digested with the indicated restriction enzymes
(BglII and EcoRV) and probed with a flanking probe (probe A) and an internal probe (probe B). (C and D) Restriction maps of the wild-type
(C) and mutant (D) Gad67 genes. The probes used in the Southern blot analysis and the sizes of the bands detected are indicated below the maps.
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nation of the palates in Gad67 mutants. The palates of 25
Gad67 homozygous mutants were examined. Overall, the cleft
palate was observed in 92% (23 of 25) of the homozygotes and
was absent in all of the heterozygous and wild-type progeny.
The cleft palate phenotype observed in the Gad67 homozy-
gotes is always a complete cleft of the secondary palate (Fig.
3 A and B). In these homozygotes, the cleft of the palatal
shelves is wide, clearly revealing the bones of the nasal cavity
(Fig. 3 B and D). Coronal sections of Gad67 (2y2) newborns
and E18.5 day fetuses show that the palatal shelves did elevate
but had failed to fuse (data not shown). In the Gad67 mutants,
some narrowing of the maxilla was observed; however, no
defects in the other bones and cartilages derived from the first
pharyngeal arch were found (Fig. 3 and data not shown). In
particular, the mandible is of normal size and morphology. No
defects were found in the hyoid bone or in the thyroid and
cricoid cartilages that are derived from the more posterior
pharyngeal arches. This analysis shows that the craniofacial
defect in the Gad67 (2y2) mutants is a specific defect in
palatogenesis.
The cleft palate phenotype in mice mutant for the GABA-
synthesizing enzyme Gad67 indicates a role for GABA func-
tion in the development of the palate. The striking similarity
between the cleft palate seen in the Gad67 (2y2) mice and the
defect reported in the b-3 GABAA receptor subunit mutant
suggests that GABA signaling through GABAA receptors is
required for normal development of the mouse palate. Con-
sistent with a direct role of GABA signaling in palatogenesis,
GABA has been detected in the developing mouse palate (12).
In addition to genetic observations, it has been shown that
drugs altering GABA signaling can induce cleft palate in
developing mice. The benzodiazepine drug diazepam can
induce cleft palate when administered to pregnant mice during
a critical period of palatogenesis (13, 14). Diazepam potenti-
ates GABA activation of GABAA receptors, increasing GABA
function. The induction of cleft palate both by loss-of-function
mutations and by an enhancement of function by benzodiaz-
epines suggests that a process during palatogenesis requires a
specific range of GABA signaling for normal development. In
humans, a link between benzodiazepine use during pregnancy
and craniofacial defects has been reported (23–25) but is
controversial (26). The highly penetrant cleft palate phenotype
seen in our mice and in the GABAA receptor knockout
indicates that the role of benzodiazepines in human craniofa-
cial defects should be carefully reexamined given the wide-
spread use of these drugs.
In humans, isolated cleft palate is common and has a
complex multifactorial etiology (27). At present, no human
syndromes or disorders that feature cleft palate map near the
Gad67 gene. In mice, Gad67 is closely linked to two other
mutations that cause craniofacial defects including cleft palate,
the spontaneous mutation First arch (Far) and a targeted
disruption of the homeobox gene Dlx-2. These genes map near
Gad67, very close to the HoxD complex on chromosome 2. In
contrast to the phenotypes of the Dlx-2 and Far mutants, the
effect of the Gad67 mutation is specific to development of the
palate with no alterations in other craniofacial structures (22,
28). It is notable that this 6-centimorgan region of chromo-
some 2 contains a high density of genes involved in develop-
ment, including craniofacial formation and palatogenesis. The
cleft palate phenotype in mice mutant for Gad67 or for the b-3
subunit of the GABAA receptor suggests that genetic or
environmental perturbations of GABA pathways during fetal
development can alter palatogenesis. Genes encoding the
enzymes of GABA metabolism and those encoding GABA
receptors should be considered as candidates for loci involved
in the etiology of human cleft palate.
Gene targeting has also been used to inactivate the Gad65
gene in mice (S. Kash and S. Baekkeskov, personal commu-
nication). Unlike Gad67 mutants, Gad65 homozygotes are
viable but exhibit temporal lobe epilepsy. The availability of
mice deficient in both Gad loci will allow tests of synergistic
interactions and functional redundancies between the two
genes. It will be of interest to examine craniofacial develop-
ment and the neuroanatomy of Gad double mutants. In
addition, new seizure phenotypes may be revealed in Gad65
(1y2)yGad67 (1y2) and Gad65 (2y2)yGad67 (1y2) mice,
providing further insight into the genetic mechanisms of
epilepsy.
Table 1. Gad67 intercross progency genotypes
Stage 1y1 1y2 2y2
Late gestation 21 39 22
Newborn 24 42 12
Adult 28 43 0
Late gestation fetuses were removed by caesarean section on
E16.5–E18.5. Adults were genotyped at 4–6 weeks old. Numbers of
animals with a specific genotype are shown.
FIG. 2. RNase protection analysis of the Gad67 and Gad65 genes
in Gad67 mutants. (A) The position of the Gad67 RNase protection
probe (RNAP probe) is shown relative to the published cDNA
sequence. The shaded portion of the cDNA corresponds to the Gad67
coding sequence. The position of the Neo insertion into the coding
sequence in the Gad67 mutant allele is indicated (MC1NEOpA).
(B–D) RNase protection of Gad67 RNA. Total RNA (25 mg) from
individual E18.5 day mouse heads of the indicated genotype (hetero-
zygote 1y1 and homozygous mutant 2y2) and 5 mg of adult brain
RNA (brain) were subjected to RNase protection analysis with the
Gad67 probe (B), the Gad65 probe (C), and a control GAPDH probe
(D). Undigested probe (Probe) is shown for the Gad65 and Gad67
assays (B and C).
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